Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.
Journal: Cancer research communications
Published: July 20, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.
Journal: Cancers
Published: April 02, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 04, 2026
Unravelling Salvage Re-irradiation for Locally Recurrent Prostate Cancer: Challenges and Complexities.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: December 05, 2025
Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: November 18, 2025
Reirradiation Options for Previously Irradiated Prostate Cancer: Is It Feasible to Randomise Between Treatment With Stereotactic Body Radiotherapy (SBRT) Versus High-Dose-Rate Brachytherapy?
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: September 24, 2025
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer.
Journal: NPJ precision oncology
Published: July 18, 2025
Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Repository.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: July 02, 2025
Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: June 10, 2025
Last Updated: 09/26/2026